Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Increase in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) was the recipient of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 3,100,000 shares, a growth of 29.2% from the January 31st total of 2,400,000 shares. Approximately 15.1% of the shares of the stock are sold short. Based on an average daily volume of 327,700 shares, the days-to-cover ratio is presently 9.5 days.

Analyst Ratings Changes

Separately, Morgan Stanley reduced their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd.

Insider Transactions at Fractyl Health

In other news, insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Harith Rajagopalan sold 90,972 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at $894,218.78. The trade was a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GUTS. Beta Wealth Group Inc. purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $44,000. Massachusetts Financial Services Co. MA boosted its position in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after buying an additional 49,289 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after buying an additional 29,262 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after buying an additional 7,397 shares during the period. Finally, HighTower Advisors LLC purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $38,000.

Fractyl Health Trading Down 3.8 %

NASDAQ GUTS traded down $0.06 during trading hours on Tuesday, hitting $1.50. 288,648 shares of the company were exchanged, compared to its average volume of 306,811. The stock has a 50-day moving average price of $1.76 and a 200 day moving average price of $2.28. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. Fractyl Health has a 52 week low of $1.37 and a 52 week high of $10.18. The stock has a market cap of $72.15 million and a PE ratio of -0.12.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08). Analysts forecast that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.